GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reaffirmed by stock analysts at Credit Suisse Group in a research report issued on Monday, ThisIsMoney.Co.Uk reports.
A number of other brokerages also recently commented on GSK. Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research note on Monday, January 21st. Liberum Capital reiterated a “hold” rating and set a GBX 1,510 ($19.73) target price on shares of GlaxoSmithKline in a research note on Monday, January 21st. HSBC set a GBX 1,820 ($23.78) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Friday, January 25th. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Thursday, January 31st. Finally, Jefferies Financial Group set a GBX 1,750 ($22.87) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Thursday, January 31st. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of GBX 1,526.14 ($19.94).
GlaxoSmithKline stock opened at GBX 1,544.60 ($20.18) on Monday. GlaxoSmithKline has a twelve month low of GBX 1,408.80 ($18.41) and a twelve month high of GBX 1,648.80 ($21.54). The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. The firm has a market cap of $76.41 billion and a PE ratio of 19.68.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: How does new data get added to a blockchain?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.